Health Care [ 8/12 ] | Pharmaceuticals [ 29/73 ]
NASDAQ | Common Stock
Elicio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies for the treatment of cancer.
Its lead product candidate is ELI-002, a multivalent lymph node"targeted amphiphile (AMP) peptide vaccine that is in Phase II clinical trial to target seven Kirsten rat sarcoma viral oncogene homolog driver mutations.
The company also develops ELI-007, a multivalent lymph node"targeted AMP peptide vaccine in preclinical studies for the treatment of mutant b-raf murine sarcoma viral oncogene homolog B1-driven cancers; and ELI-008, a multivalent lymph node"targeted AMP peptide vaccine in preclinical studies for use in the treatment of mutated tumor protein p53 expressing cancers.
Elicio Therapeutics, Inc. is headquartered in Boston, Massachusetts.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 13, 25 | -0.87 Increased by +24.35% | -0.73 Decreased by -19.18% |
| Mar 27, 25 | -1.02 Increased by +41.71% | -0.88 Decreased by -16.57% |
| Nov 7, 24 | -1.39 Decreased by -9.45% | -0.73 Decreased by -90.41% |
| Aug 13, 24 | -0.64 Increased by +73.74% | -0.96 Increased by +33.33% |
| May 15, 24 | -1.15 Increased by +23.67% | -1.09 Decreased by -5.50% |
| Mar 29, 24 | -1.75 Increased by +16.67% | -0.78 Decreased by -124.36% |
| Nov 9, 23 | -1.27 Increased by +57.67% | -0.80 Decreased by -58.75% |
| Aug 11, 23 | -2.44 Increased by +18.75% | - |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Mar 31, 25 | 0.00 Decreased by N/A% | -11.21 M Increased by +5.23% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 24 | 1.17 M Increased by +N/A% | -14.00 M Decreased by -56.49% | Decreased by -1.20 K% Decreased by N/A% |
| Sep 30, 24 | 0.00 Decreased by N/A% | -18.84 M Decreased by -76.75% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 24 | 0.00 Decreased by N/A% | -7.23 M Increased by +4.37% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 24 | 0.00 Decreased by N/A% | -11.83 M Decreased by -47.30% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 23 | 0.00 Decreased by N/A% | -8.95 M Decreased by -34.56% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 23 | 0.00 Decreased by N/A% | -10.66 M Decreased by -48.07% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 23 | 0.00 Decreased by N/A% | -7.56 M Decreased by -3.56% | Decreased by N/A% Decreased by N/A% |